Association of Interleukin-10 −3575T>A and −1082A>G polymorphisms with non-Hodgkin lymphoma susceptibility: a comprehensive review and meta-analysis

Molecular Genetics and Genomics

Volumn 290, Issue 6, 2015, Pages 2063-2073

  Zhang, Yan ^a   Xia, Zu Guang ^d,e   Zhu, Jin Hong ^f   Chen, Min Bin ^a   Wang, Tong Min ^c   Shen, Wen Xiang ^a   He, Jing ^b,c  

^a KUNSHAN FIRST PEOPLE S HOSPITAL AFFILIATED TO JIANGSU UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^d FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^e FUDAN UNIVERSITY   (China)

^f HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Interleukin 10; Meta analysis; Non Hodgkin lymphoma; Polymorphism

Indexed keywords

INTERLEUKIN 10;

ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; FOLLICULAR LYMPHOMA; GENE FREQUENCY; GENETIC MODEL; GENOTYPE; HUMAN; LARGE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-10; LYMPHOMA, NON-HODGKIN; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84947869723     PISSN: 16174615     EISSN: 16174623     Source Type: Journal    
DOI: 10.1007/s00438-015-1058-y     Document Type: Article

References (54)

1. Andrie E, Michos A, Kalampoki V, Pourtsidis A, Moschovi M, Polychronopoulou S, Athanasiadou-Piperopoulou F, Kalmanti M, Hatzakis A, Paraskevis D, Nieters A, Petridou ET (2009) Genetic variants in immunoregulatory genes and risk for childhood lymphomas. Eur J Haematol 83:334–342
2. Berglund M, Thunberg U, Roos G, Rosenquist R, Enblad G (2005) The interleukin-10 gene promoter polymorphism (-1082) does not correlate with clinical outcome in diffuse large B-cell lymphoma. Blood 105:4894–4895 author reply 4895
3. Bogunia-Kubik K, Mazur G, Wrobel T, Kuliczkowski K, Lange A (2008) Interleukin-10 gene polymorphisms influence the clinical course of non-Hodgkin’s lymphoma. Tissue Antigens 71:146–150
4. Colt JS, Rothman N, Severson RK, Hartge P, Cerhan JR, Chatterjee N, Cozen W, Morton LM, De Roos AJ, Davis S, Chanock S, Wang SS (2009) Organochlorine exposure, immune gene variation, and risk of non-Hodgkin lymphoma. Blood 113:1899–1905
5. Cunningham LM, Chapman C, Dunstan R, Bell MC, Joske DJ (2003) Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma 44:251–255
6. Deng Q, Zheng T, Lan Q, Lan Y, Holford T, Chen Y, Dai M, Leaderer B, Boyle P, Chanock SJ, Rothman N, Zhang Y (2013) Occupational solvent exposure, genetic variation in immune genes, and the risk for non-Hodgkin Lymphoma. Eur J Cancer Prev 22:77–82
7. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188
8. Domingo-Domenech E, Benavente Y, Gonzalez-Barca E, Montalban C, Guma J, Bosch R, Wang SS, Lan Q, Whitby D, Fernandez de Sevilla A, Rothman N, de Sanjose S (2007) Impact of interleukin-10 polymorphisms (-1082 and -3575) on the survival of patients with lymphoid neoplasms. Haematologica 92:1475–1481
9. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
10. Ennas MG, Moore PS, Zucca M, Angelucci E, Cabras MG, Melis M, Gabbas A, Serpe R, Madeddu C, Scarpa A, Cocco P (2008) Interleukin-1B (IL1B) and interleukin-6 (IL6) gene polymorphisms are associated with risk of chronic lymphocytic leukaemia. Hematol Oncol 26:98–103
11. Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, Huizinga TW (1998) Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA 95:9465–9470
12. Fernberg P, Chang ET, Duvefelt K, Hjalgrim H, Eloranta S, Sorensen KM, Porwit A, Humphreys K, Melbye M, Ekstrom Smedby K (2010) Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma. Cancer Causes Control 21:759–769
13. Grulich AE, Vajdic CM, Cozen W (2007) Altered immunity as a risk factor for non-Hodgkin lymphoma. Cancer Epidemiol Biomark Prev 16:405–408
14. Guzowski D, Chandrasekaran A, Gawel C, Palma J, Koenig J, Wang XP, Dosik M, Kaplan M, Chu CC, Chavan S, Furie R, Albesiano E, Chiorazzi N, Goodwin L (2005) Analysis of single nucleotide polymorphisms in the promoter region of interleukin-10 by denaturing high-performance liquid chromatography. J Biomol Tech 16:154–166
15. Habermann TM, Wang SS, Maurer MJ, Morton LM, Lynch CF, Ansell SM, Hartge P, Severson RK, Rothman N, Davis S, Geyer SM, Cozen W, Chanock SJ, Cerhan JR (2008) Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Blood 112:2694–2702
16. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (2000) The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting—Airlie House, Virginia, November 1997. Hematol J 1:53–66
17. He J, Qiu LX, Wang MY, Hua RX, Zhang RX, Yu HP, Wang YN, Sun MH, Zhou XY, Yang YJ, Wang JC, Jin L, Wei QY, Li J (2012) Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations. Hum Genet 131:1235–1244
18. He J, Shi TY, Zhu ML, Wang MY, Li QX, Wei QY (2013) Associations of Lys939Gln and Ala499Val polymorphisms of the XPC gene with cancer susceptibility: a meta-analysis. Int J Cancer 133:1765–1775
19. He J, Liao XY, Zhu JH, Xue WQ, Shen GP, Huang SY, Chen W, Jia WH (2014) Association of MTHFR C677T and A1298C polymorphisms with non-Hodgkin lymphoma susceptibility: evidence from a meta-analysis. Sci Rep 4:6159
20. Heemann C, Kreuz M, Stoller I, Schoof N, von Bonin F, Ziepert M, Loffler M, Jung W, Pfreundschuh M, Trumper L, Kube D (2012) Circulating levels of TNF receptor II are prognostic for patients with peripheral T-cell non-Hodgkin lymphoma. Clin Cancer Res 18:3637–3647
21. Holm K, Melum E, Franke A, Karlsen TH (2010) SNPexp—a web tool for calculating and visualizing correlation between HapMap genotypes and gene expression levels. BMC Bioinformatics 11:600
22. Hosgood HD 3rd, Au WY, Kim HN, Liu J, Hu W, Tse J, Song B, Wong KF, Lee JJ, Chanock SJ, Siu LP, Purdue MP, Shin MH, Yu J, Liang R, Kim HJ, Rothman N, Lan Q (2013) IL10 and TNF variants and risk of non-Hodgkin lymphoma among three Asian populations. Int J Hematol 97:793–799
23. Howell WM, Rose-Zerilli MJ (2006) Interleukin-10 polymorphisms, cancer susceptibility and prognosis. Fam Cancer 5:143–149
24. Hutchins AP, Diez D, Miranda-Saavedra D (2013) The IL-10/STAT3-mediated anti-inflammatory response: recent developments and future challenges. Brief Funct Genomics 12:489–498
25. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90
26. Kube D, Hua TD, Kloss M, Kulle B, Brockmoller J, Wojnowski L, Loffler M, Pfreundschuh M, Trumper L (2007) The interleukin-10 gene promoter polymorphism -1087AG does not correlate with clinical outcome in non-Hodgkin’s lymphoma. Genes Immun 8:164–167
27. Lan Q, Zheng T, Rothman N, Zhang Y, Wang SS, Shen M, Berndt SI, Zahm SH, Holford TR, Leaderer B, Yeager M, Welch R, Boyle P, Zhang B, Zou K, Zhu Y, Chanock S (2006) Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 107:4101–4108
28. Lech-Maranda E, Baseggio L, Bienvenu J, Charlot C, Berger F, Rigal D, Warzocha K, Coiffier B, Salles G (2004) Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 103:3529–3534
29. Lech-Maranda E, Baseggio L, Charlot C, Rigal D, Berger F, Jamroziak K, Warzocha K, Coiffier B, Salles G (2007) Genetic polymorphisms in the proximal IL-10 promoter and susceptibility to non-Hodgkin lymphoma. Leuk Lymphoma 48:2235–2238
30. Lech-Maranda E, Bienvenu J, Broussais-Guillaumot F, Warzocha K, Michallet AS, Robak T, Coiffier B, Salles G (2010) Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index. Arch Immunol Ther Exp (Warsz) 58:131–141
31. Lech-Maranda E, Mlynarski W, Grzybowska-Izydorczyk O, Borowiec M, Pastorczak A, Cebula-Obrzut B, Klimkiewicz-Wojciechowska G, Wcislo M, Majewski M, Kotkowska A, Robak T, Warzocha K (2013) Polymorphisms of TNF and IL-10 genes and clinical outcome of patients with chronic lymphocytic leukemia. Genes Chromosomes Cancer 52:287–296
32. Lee JJ, Kim DH, Lee NY, Sohn SK, Kim JG, Kim HJ, Do YR, Park YH (2007) Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas. Br J Haematol 137:329–336
33. Liang XS, Caporaso N, McMaster ML, Ng D, Landgren O, Yeager M, Chanock S, Goldin LR (2009) Common genetic variants in candidate genes and risk of familial lymphoid malignancies. Br J Haematol 146:418–423
34. Lim YY, Chin YM, Tai MC, Fani S, Chang KM, Ong TC, Bee PC, Gan GG, Ng CC (2015) Analysis of interleukin-10 promoter single nucleotide polymorphisms and risk of non-Hodgkin lymphoma in a Malaysian population. Leuk Lymphoma 56:163–168
35. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748
36. Morton LM, Wang SS, Cozen W, Linet MS, Chatterjee N, Davis S, Severson RK, Colt JS, Vasef MA, Rothman N, Blair A, Bernstein L, Cross AJ, De Roos AJ, Engels EA, Hein DW, Hill DA, Kelemen LE, Lim U, Lynch CF, Schenk M, Wacholder S, Ward MH, Hoar Zahm S, Chanock SJ, Cerhan JR, Hartge P (2008) Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood 112:5150–5160
37. Nieters A, Beckmann L, Deeg E, Becker N (2006) Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun 7:615–624
38. Persico M, Capasso M, Persico E, Masarone M, Renzo A, Spano D, Bruno S, Iolascon A (2006) Interleukin-10 -1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection. J Hepatol 45:779–785
39. Purdue MP, Hartge P, Davis S, Cerhan JR, Colt JS, Cozen W, Severson RK, Li Y, Chanock SJ, Rothman N, Wang SS (2007a) Sun exposure, vitamin D receptor gene polymorphisms and risk of non-Hodgkin lymphoma. Cancer Causes Control 18:989–999
40. Purdue MP, Lan Q, Kricker A, Grulich AE, Vajdic CM, Turner J, Whitby D, Chanock S, Rothman N, Armstrong BK (2007b) Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin lymphoma study. Carcinogenesis 28:704–712
41. Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT, Spinelli JJ, Willett E, De Sanjose S, Cocco P, Berndt SI, Brennan P, Brooks-Wilson A, Wacholder S, Becker N, Hartge P, Zheng T, Roman E, Holly EA, Boffetta P, Armstrong B, Cozen W, Linet M, Bosch FX, Ennas MG, Holford TR, Gallagher RP, Rollinson S, Bracci PM, Cerhan JR, Whitby D, Moore PS, Leaderer B, Lai A, Spink C, Davis S, Bosch R, Scarpa A, Zhang Y, Severson RK, Yeager M, Chanock S, Nieters A (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the interlymph consortium. Lancet Oncol 7:27–38
42. Shouval DS, Biswas A, Goettel JA, McCann K, Conaway E, Redhu NS, Mascanfroni ID, Al Adham Z, Lavoie S, Ibourk M, Nguyen DD, Samsom JN, Escher JC, Somech R, Weiss B, Beier R, Conklin LS, Ebens CL, Santos FG, Ferreira AR, Sherlock M, Bhan AK, Muller W, Mora JR, Quintana FJ, Klein C, Muise AM, Horwitz BH, Snapper SB (2014) Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. Immunity 40:706–719
43. Stern M, Opelz G, Dohler B, Hess C (2010) Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma. Blood 115:3960–3965
44. Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, Thorne N, Redon R, Bird CP, de Grassi A, Lee C, Tyler-Smith C, Carter N, Scherer SW, Tavare S, Deloukas P, Hurles ME, Dermitzakis ET (2007) Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 315:848–853
45. Tarabar O, Cikota-Aleksic B, Tukic L, Milanovic N, Aleksic A, Magic Z (2014) Association of interleukin-10, tumor necrosis factor-alpha and transforming growth factor-beta gene polymorphisms with the outcome of diffuse large B-cell lymphomas. Int J Clin Oncol 19:186–192
46. Wang SS, Cerhan JR, Hartge P, Davis S, Cozen W, Severson RK, Chatterjee N, Yeager M, Chanock SJ, Rothman N (2006) Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res 66:9771–9780
47. Wang SS, Cozen W, Cerhan JR, Colt JS, Morton LM, Engels EA, Davis S, Severson RK, Rothman N, Chanock SJ, Hartge P (2007) Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. Cancer Res 67:5042–5054
48. Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI, Vandenbroucke JP (1997) Genetic influence on cytokine production and fatal meningococcal disease. Lancet 349:170–173
49. Wong HL, Breen EC, Pfeiffer RM, Aissani B, Martinson JJ, Margolick JB, Kaslow RA, Jacobson LP, Ambinder RF, Chanock S, Martinez-Maza O, Rabkin CS (2010) Cytokine signaling pathway polymorphisms and AIDS-related non-Hodgkin lymphoma risk in the multicenter AIDS cohort study. AIDS 24:1025–1033
50. Wu B, Cheng Y (2014) Upregulation of innate immune responses in a T cell/histiocyte-rich large B cell lymphoma patient with significant autoimmune disorders mimicking systemic lupus erythematosus. Ann Hematol 93:353–354
51. Yri OE, Ekstrom PO, Hilden V, Gaudernack G, Liestol K, Smeland EB, Holte H (2013) Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab. Leuk Lymphoma 54:2205–2214
52. Yu X, Chen B, Cheng J, Gao C, Zhang X, Bao W (2014) The interleukin-10 −1082A>G polymorphism and lymphoma risk: a meta-analysis. Cancer Biomark 14:381–388
53. Zhang Y, Wang MY, He J, Wang JC, Yang YJ, Jin L, Chen ZY, Ma XJ, Sun MH, Xia KQ, Hong XN, Wei QY, Zhou XY (2012) Tumor necrosis factor-alpha induced protein 8 polymorphism and risk of non-Hodgkin’s lymphoma in a Chinese population: a case-control study. PLoS One 7:e37846
54. Zhang Y, Yang D, Zhu JH, Chen MB, Shen WX, He J (2015) The association between NQO1 Pro187Ser polymorphism and urinary system cancer susceptibility: a meta-analysis of 22 studies. Cancer Invest 33:39–40